BRIEF-Vir Biotechnology Announces First Patient Dosed In Part 3 Of Phase 1 Trial

Reuters
Oct 10
BRIEF-<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Announces First Patient Dosed In Part 3 Of Phase 1 Trial

Oct 9 (Reuters) - Vir Biotechnology Inc VIR.O:

  • VIR BIOTECHNOLOGY ANNOUNCES FIRST PATIENT DOSED IN PART 3 OF PHASE 1 TRIAL OF PSMA-TARGETING PRO-XTEN® DUAL-MASKED T-CELL ENGAGER VIR-5500 IN COMBINATION WITH ANDROGEN RECEPTOR PATHWAY INHIBITORS FOR THE TREATMENT OF METASTATIC PROSTATE CANCER

Source text: ID:nBw6np3xTa

Further company coverage: VIR.O

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10